Chronic Lymphocytic Leukaemia (CLL)

Also known as: Chronic Lymphocytic Leukemias / Chronic lymphocytic leukemia / Leukemia, Chronic Lymphocytic / Chronic Lymphocytic Leukemia (CLL) / Chronic Lymphoid Leukemia / Chronic Lymphatic Leukemia / Leukemia, Chronic Lymphatic / Chronic Lymphocytic Leukaemia / Leukaemias chronic lymphocytic / Leukemia lymphocytic chronic / B-cell chronic lymphocytic leukemia / CLL / Chronic lymphoid leukaemia / Lymphoid leukaemia, chronic / Lymphoid leukemia, chronic / Chronic lymphatic leukaemia / Leukaemia lymphocytic chronic / Chronic lymphocytic leukaemia NOS / Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoplasmacytic leukemia

DrugDrug NameDrug Description
DB00087AlemtuzumabHumanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.
DB06769BendamustineBendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
DB00291ChlorambucilA nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
DB00531CyclophosphamidePrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem]
DB09053IbrutinibIbrutinib is a small molecule anti-cancer drug that targets B-cell malignancies. In November 2013 ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Ibrutinib is also indicated for the treatment of patients with Waldenstr├Âm's Macroglobulinemia (WM). Ibrutinib is marketed under the brand Imbruvica┬« by Janssen Biotech, Inc., but was first designed and synthesized at Celera Genomics in 2007. Ibrutinib was approved for use in chronic graft versus host disease in August 2017 [L937].
DB00888MechlorethamineA vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. [PubChem] The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCL.
DB06650OfatumumabOfatumumab is a human monoclonal antibody for the CD20 protein. Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature B-lymphocyte) and on B-cell CLL. The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates immune effector functions to result in B-cell lysis in vitro. Ofatumumab received FDA approval on April 17, 2014, for use in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. Ofatumumab was also approved by Health Canada on August 13th, 2012.
DB00552PentostatinA potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. [PubChem]
DB11581VenetoclaxVenetoclax is an oral selective inhibitor of B-Cell Lymphoma-2 (BCL-2), an antiapoptotic protein that plays a key role in the development of chronic lymphocytic leukemia (CLL) cells. BCL-2 and its related proteins BCL-XL and MCL-1 bind to and sequester pro-apoptotic signals in the cell, causing a down-regulation of apoptosis. As an oncogene and an important regulator of apoptosis, BCL-2 overexpression therefore results in increased tumour cell survival and resistance to chemotherapy. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. Compared to navitoclax, a duel inhibitor of BCL-2 and BCL-XL, venetoclax use results in significantly less platelet killing and thrombocytopenia. This is due to its specificity for BCL-2 and sparing of BCL-XL, which is required for platelet survival. In 2015, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to venetoclax for patients with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation. It was approved by the FDA in April 2016.
DrugDrug NameTargetType
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB06769BendamustineCytochrome P450 1A2enzyme
DB00291ChlorambucilDNAtarget
DB00291ChlorambucilGlutathione S-transferase Penzyme
DB00291ChlorambucilSolute carrier organic anion transporter family member 1A2transporter
DB00531CyclophosphamideCytochrome P450 2B6enzyme
DB00531CyclophosphamideCytochrome P450 2C9enzyme
DB00531CyclophosphamideCytochrome P450 3A4enzyme
DB00531CyclophosphamideCytochrome P450 2C19enzyme
DB00531CyclophosphamideCytochrome P450 2A6enzyme
DB00531CyclophosphamideCytochrome P450 2C18enzyme
DB00531CyclophosphamideCytochrome P450 2C8enzyme
DB00531CyclophosphamideCytochrome P450 2D6enzyme
DB00531CyclophosphamideCytochrome P450 3A7enzyme
DB00531CyclophosphamideCytochrome P450 3A5enzyme
DB00531CyclophosphamideDNAtarget
DB00531CyclophosphamideNuclear receptor subfamily 1 group I member 2target
DB00531CyclophosphamideMultidrug resistance protein 1transporter
DB09053IbrutinibTyrosine-protein kinase BTKtarget
DB09053IbrutinibCytochrome P450 3A4enzyme
DB09053IbrutinibCytochrome P450 3A5enzyme
DB09053IbrutinibCytochrome P450 2D6enzyme
DB00888MechlorethamineDNAtarget
DB06650OfatumumabB-lymphocyte antigen CD20target
DB00552PentostatinAdenosine deaminasetarget
DB11581VenetoclaxApoptosis regulator Bcl-2target
DB11581VenetoclaxCytochrome P450 3A4enzyme
DB11581VenetoclaxMultidrug resistance protein 1transporter
DB11581VenetoclaxATP-binding cassette sub-family G member 2transporter
DrugDrug NamePhaseStatusCount
DB00313Valproic Acid0Completed1
DB00541Vincristine0Terminated1
DB11703Acalabrutinib1Active Not Recruiting2
DB00087Alemtuzumab1Completed1
DB05220Alisertib1Active Not Recruiting1
DB03496Alvocidib1Completed1
DB03496Alvocidib1Terminated1
DB09312Antilymphocyte immunoglobulin (horse)1Recruiting1
DB00098Antithymocyte immunoglobulin (rabbit)1Recruiting1
DB00928Azacitidine1Completed1
DB06769Bendamustine1Active Not Recruiting4
DB06769Bendamustine1Completed4
DB06769Bendamustine1Recruiting1
DB06769Bendamustine1Withdrawn1
DB00188Bortezomib1Completed1
DB01008Busulfan1Recruiting1
DB12740CC-1151Active Not Recruiting1
DB01413Cefepime1Completed1
DB00493Cefotaxime1Terminated1
DB00291Chlorambucil1Active Not Recruiting1
DB00291Chlorambucil1Completed1
DB00291Chlorambucil1Recruiting1
DB01188Ciclopirox1Completed1
DB04815Clioquinol1Terminated1
DB00631Clofarabine1Terminated1
DB06189Clofarabine1Terminated1
DB00631Clofarabine1Withdrawn1
DB06189Clofarabine1Withdrawn1
DB00531Cyclophosphamide1Completed1
DB00531Cyclophosphamide1Recruiting3
DB00531Cyclophosphamide1Terminated2
DB01254Dasatinib1Completed1
DB01254Dasatinib1Withdrawn1
DB08908Dimethyl fumarate1Recruiting1
DB12021Dinaciclib1Completed1
DB11952Duvelisib1Completed1
DB11952Duvelisib1Withdrawn1
DB01590Everolimus1Completed1
DB01073Fludarabine1Completed2
DB01073Fludarabine1Recruiting4
DB01073Fludarabine1Terminated1
DB09053Ibrutinib1Recruiting4
DB09053Ibrutinib1Terminated2
DB09054Idelalisib1Active Not Recruiting1
DB09054Idelalisib1Completed3
DB09054Idelalisib1Recruiting1
DB09054Idelalisib1Terminated1
DB06186Ipilimumab1Active Not Recruiting1
DB01026Ketoconazole1Completed1
DB00480Lenalidomide1Active Not Recruiting1
DB00480Lenalidomide1Completed5
DB00480Lenalidomide1Recruiting1
DB00480Lenalidomide1Terminated3
DB06162Lumiliximab1Completed1
DB12852MK-07521Terminated1
DB01042Melphalan1Recruiting1
DB00563Methotrexate1Recruiting1
DB00688Mycophenolate mofetil1Recruiting1
DB05764Navitoclax1Active Not Recruiting1
DB12340Navitoclax1Active Not Recruiting1
DB05764Navitoclax1Completed3
DB11793Niraparib1Completed1
DB12191Obatoclax1Completed1
DB08935Obinutuzumab1Active Not Recruiting3
DB08935Obinutuzumab1Recruiting4
DB06650Ofatumumab1Active Not Recruiting1
DB06650Ofatumumab1Completed2
DB00552Pentostatin1Active Not Recruiting1
DB06809Plerixafor1Completed1
DB06809Plerixafor1Terminated1
DB12240Polatuzumab Vedotin1Completed1
DB12146Rigosertib1Completed1
DB00073Rituximab1Active Not Recruiting6
DB00073Rituximab1Completed8
DB00073Rituximab1Recruiting2
DB00073Rituximab1Terminated5
DB00641Simvastatin1Completed1
DB11764Spebrutinib1Completed1
DB12756TAK-9011Completed1
DB00864Tacrolimus1Recruiting2
DB11760Talazoparib1Completed1
DB05134Tanespimycin1Terminated1
DB06398Tanespimycin1Terminated1
DB12226Terameprocol1Terminated1
DB06273Tocilizumab1Recruiting1
DB00081Tositumomab1Unknown Status1
DB11850Ublituximab1Completed1
DB11850Ublituximab1Recruiting1
DB11930Varlilumab1Active Not Recruiting1
DB11581Venetoclax1Active Not Recruiting4
DB11581Venetoclax1Withdrawn1
DB02546Vorinostat1Active Not Recruiting1
DB12400Voxtalisib1Completed1
DB05149XL8441Terminated1
DB06361rsPSMA Vaccine1Completed1
DB04974AP19031 / 2Recruiting1
DB11703Acalabrutinib1 / 2Active Not Recruiting1
DB11703Acalabrutinib1 / 2Not Yet Recruiting1
DB11703Acalabrutinib1 / 2Recruiting1
DB00087Alemtuzumab1 / 2Completed1
DB04975Banoxantrone1 / 2Unknown Status1
DB06769Bendamustine1 / 2Completed4
DB09052Blinatumomab1 / 2Withdrawn1
DB01008Busulfan1 / 2Completed1
DB00291Chlorambucil1 / 2Completed1
DB00291Chlorambucil1 / 2Terminated1
DB00242Cladribine1 / 2Unknown Status1
DB09110Coenzyme M1 / 2Recruiting1
DB00531Cyclophosphamide1 / 2Active Not Recruiting2
DB00531Cyclophosphamide1 / 2Completed2
DB00531Cyclophosphamide1 / 2Recruiting1
DB00531Cyclophosphamide1 / 2Withdrawn1
DB00091Cyclosporine1 / 2Completed1
DB01254Dasatinib1 / 2Unknown Status2
DB01234Dexamethasone1 / 2Completed1
DB12021Dinaciclib1 / 2Active Not Recruiting1
DB11952Duvelisib1 / 2Active Not Recruiting1
DB06210Eltrombopag1 / 2Terminated1
DB00005Etanercept1 / 2Completed1
DB00099Filgrastim1 / 2Completed1
DB01073Fludarabine1 / 2Active Not Recruiting2
DB01073Fludarabine1 / 2Completed4
DB01073Fludarabine1 / 2Recruiting1
DB01073Fludarabine1 / 2Withdrawn1
DB00056Gemtuzumab ozogamicin1 / 2Completed1
DB09053Ibrutinib1 / 2Active Not Recruiting2
DB09053Ibrutinib1 / 2Recruiting2
DB09053Ibrutinib1 / 2Withdrawn1
DB00619Imatinib1 / 2Terminated1
DB00034Interferon Alfa-2a, Recombinant1 / 2Withdrawn1
DB00480Lenalidomide1 / 2Completed7
DB00480Lenalidomide1 / 2Unknown Status1
DB01042Melphalan1 / 2Completed1
DB00563Methotrexate1 / 2Completed1
DB12943Milatuzumab1 / 2Unknown Status1
DB12824Monalizumab1 / 2Recruiting1
DB12688Moxetumomab Pasudotox1 / 2Completed1
DB00688Mycophenolate mofetil1 / 2Completed1
DB05764Navitoclax1 / 2Completed1
DB08935Obinutuzumab1 / 2Active Not Recruiting1
DB08935Obinutuzumab1 / 2Recruiting1
DB06650Ofatumumab1 / 2Active Not Recruiting1
DB06650Ofatumumab1 / 2Withdrawn1
DB11697Pacritinib1 / 2Withdrawn1
DB00008Peginterferon alfa-2a1 / 2Withdrawn1
DB09037Pembrolizumab1 / 2Recruiting3
DB00205Pyrimethamine1 / 2Recruiting1
DB12762Rabacfosadine1 / 2Terminated1
DB00073Rituximab1 / 2Active Not Recruiting2
DB00073Rituximab1 / 2Completed6
DB00073Rituximab1 / 2Unknown Status1
DB08877Ruxolitinib1 / 2Completed1
DB11850Ublituximab1 / 2Active Not Recruiting2
DB11850Ublituximab1 / 2Completed1
DB11850Ublituximab1 / 2Recruiting1
DB00313Valproic Acid1 / 2Unknown Status1
DB07232Veliparib1 / 2Completed1
DB11581Venetoclax1 / 2Active Not Recruiting1
DB02546Vorinostat1 / 2Active Not Recruiting1
DB09145Water1 / 2Completed1
DB05428motexafin gadolinium1 / 2Completed1
DB11703Acalabrutinib2Recruiting2
DB00087Alemtuzumab2Active Not Recruiting1
DB00087Alemtuzumab2Completed8
DB00087Alemtuzumab2Terminated2
DB00087Alemtuzumab2Unknown Status1
DB00437Allopurinol2Active Not Recruiting1
DB00437Allopurinol2Recruiting3
DB09312Antilymphocyte immunoglobulin (horse)2Recruiting2
DB00098Antithymocyte immunoglobulin (rabbit)2Active Not Recruiting2
DB00098Antithymocyte immunoglobulin (rabbit)2Recruiting2
DB00098Antithymocyte immunoglobulin (rabbit)2Terminated1
DB01169Arsenic trioxide2Completed1
DB11595Atezolizumab2Recruiting1
DB00995Auranofin2Completed1
DB00928Azacitidine2Recruiting1
DB00928Azacitidine2Terminated1
DB00074Basiliximab2Completed1
DB06769Bendamustine2Active Not Recruiting5
DB06769Bendamustine2Completed6
DB06769Bendamustine2Terminated2
DB06769Bendamustine2Withdrawn3
DB00112Bevacizumab2Completed1
DB00188Bortezomib2Active Not Recruiting1
DB00188Bortezomib2Recruiting1
DB11666Buparlisib2Active Not Recruiting1
DB01008Busulfan2Active Not Recruiting3
DB01008Busulfan2Recruiting2
DB01008Busulfan2Terminated2
DB12476CPG-528522Terminated1
DB00262Carmustine2Completed2
DB00262Carmustine2Terminated1
DB00493Cefotaxime2Completed1
DB00493Cefotaxime2Not Yet Recruiting1
DB00493Cefotaxime2Recruiting2
DB00291Chlorambucil2Completed2
DB00291Chlorambucil2Terminated1
DB00537Ciprofloxacin2Active Not Recruiting1
DB00242Cladribine2Terminated1
DB01211Clarithromycin2Active Not Recruiting1
DB00631Clofarabine2Terminated1
DB09110Coenzyme M2Active Not Recruiting1
DB09110Coenzyme M2Recruiting1
DB00531Cyclophosphamide2Active Not Recruiting7
DB00531Cyclophosphamide2Completed15
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting11
DB00531Cyclophosphamide2Terminated3
DB00091Cyclosporine2Active Not Recruiting2
DB00091Cyclosporine2Completed3
DB00091Cyclosporine2Recruiting4
DB00091Cyclosporine2Terminated1
DB00987Cytarabine2Completed2
DB00987Cytarabine2Terminated1
DB00012Darbepoetin alfa2Completed1
DB01254Dasatinib2Active Not Recruiting1
DB01254Dasatinib2Completed1
DB01254Dasatinib2Terminated1
DB01254Dasatinib2Unknown Status1
DB01234Dexamethasone2Completed3
DB00997Doxorubicin2Completed1
DB00254Doxycycline2Terminated1
DB06210Eltrombopag2Unknown Status1
DB12121Entospletinib2Completed1
DB12121Entospletinib2Recruiting2
DB00773Etoposide2Active Not Recruiting1
DB00773Etoposide2Completed2
DB00773Etoposide2Terminated1
DB00099Filgrastim2Active Not Recruiting3
DB00099Filgrastim2Completed2
DB00099Filgrastim2Recruiting4
DB01073Fludarabine2Active Not Recruiting9
DB01073Fludarabine2Completed17
DB01073Fludarabine2Not Yet Recruiting1
DB01073Fludarabine2Recruiting10
DB01073Fludarabine2Terminated4
DB09053Ibrutinib2Active Not Recruiting2
DB09053Ibrutinib2Not Yet Recruiting1
DB09053Ibrutinib2Recruiting7
DB09053Ibrutinib2Withdrawn1
DB09054Idelalisib2Completed1
DB09054Idelalisib2Recruiting2
DB09054Idelalisib2Suspended1
DB09054Idelalisib2Terminated1
DB09054Idelalisib2Withdrawn2
DB00724Imiquimod2Recruiting1
DB00724Imiquimod2Terminated1
DB12530Inebilizumab2Completed1
DB09570Ixazomib2Recruiting1
DB00448Lansoprazole2Active Not Recruiting1
DB00480Lenalidomide2Active Not Recruiting8
DB00480Lenalidomide2Completed12
DB00480Lenalidomide2Not Yet Recruiting1
DB00480Lenalidomide2Recruiting2
DB00480Lenalidomide2Terminated4
DB00480Lenalidomide2Unknown Status1
DB00480Lenalidomide2Withdrawn2
DB11754Lirilumab2Active Not Recruiting1
DB06162Lumiliximab2Terminated2
DB04835Maraviroc2Active Not Recruiting1
DB01042Melphalan2Completed4
DB01042Melphalan2Recruiting1
DB01042Melphalan2Terminated2
DB00563Methotrexate2Active Not Recruiting3
DB00959Methylprednisolone2Active Not Recruiting2
DB00959Methylprednisolone2Completed1
DB00916Metronidazole2Active Not Recruiting1
DB01204Mitoxantrone2Active Not Recruiting1
DB01204Mitoxantrone2Completed1
DB00688Mycophenolate mofetil2Active Not Recruiting5
DB00688Mycophenolate mofetil2Completed3
DB00688Mycophenolate mofetil2Recruiting11
DB00688Mycophenolate mofetil2Terminated2
DB01024Mycophenolic acid2Terminated1
DB05764Navitoclax2Active Not Recruiting1
DB05764Navitoclax2Completed2
DB12340Navitoclax2Completed1
DB09035Nivolumab2Recruiting1
DB05415OSI-4612Completed1
DB08935Obinutuzumab2Active Not Recruiting2
DB08935Obinutuzumab2Completed1
DB08935Obinutuzumab2Not Yet Recruiting1
DB08935Obinutuzumab2Recruiting5
DB06650Ofatumumab2Active Not Recruiting6
DB06650Ofatumumab2Completed6
DB06650Ofatumumab2Recruiting2
DB06650Ofatumumab2Suspended1
DB06650Ofatumumab2Terminated2
DB06650Ofatumumab2Withdrawn1
DB11707Olaptesed Pegol2Active Not Recruiting1
DB00552Pentostatin2Active Not Recruiting1
DB00552Pentostatin2Completed3
DB00252Phenytoin2Active Not Recruiting1
DB06809Plerixafor2Completed1
DB06809Plerixafor2Terminated1
DB00635Prednisone2Completed1
DB10415Rabbit2Active Not Recruiting1
DB00073Rituximab2Active Not Recruiting9
DB00073Rituximab2Completed18
DB00073Rituximab2Recruiting4
DB00073Rituximab2Terminated7
DB00073Rituximab2Unknown Status1
DB00073Rituximab2Withdrawn1
DB08877Ruxolitinib2Recruiting1
DB00020Sargramostim2Completed2
DB00020Sargramostim2Recruiting1
DB00877Sirolimus2Active Not Recruiting1
DB00877Sirolimus2Recruiting4
DB00398Sorafenib2Terminated1
DB10319Streptococcus pneumoniae type 1 capsular polysaccharide antigen2Active Not Recruiting1
DB10293Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen2Recruiting1
DB00864Tacrolimus2Active Not Recruiting5
DB00864Tacrolimus2Completed1
DB00864Tacrolimus2Recruiting5
DB00864Tacrolimus2Terminated1
DB01041Thalidomide2Recruiting1
DB04572Thiotepa2Recruiting2
DB04572Thiotepa2Terminated1
DB11678Treosulfan2Unknown Status1
DB11850Ublituximab2Enrolling by Invitation1
DB11850Ublituximab2Recruiting1
DB01586Ursodeoxycholic acid2Active Not Recruiting1
DB00577Valaciclovir2Completed1
DB00577Valaciclovir2Recruiting1
DB01610Valganciclovir2Completed1
DB11581Venetoclax2Active Not Recruiting3
DB11581Venetoclax2Recruiting5
DB00541Vincristine2Completed1
DB08828Vismodegib2Terminated1
DB05428motexafin gadolinium2Terminated1
DB06769Bendamustine2 / 3Completed1
DB01073Fludarabine2 / 3Completed1
DB11703Acalabrutinib3Active Not Recruiting1
DB11703Acalabrutinib3Recruiting2
DB06769Bendamustine3Active Not Recruiting5
DB06769Bendamustine3Completed1
DB06769Bendamustine3Recruiting3
DB06769Bendamustine3Terminated1
DB06769Bendamustine3Unknown Status1
DB00493Cefotaxime3Active Not Recruiting1
DB00291Chlorambucil3Active Not Recruiting4
DB00291Chlorambucil3Completed2
DB00291Chlorambucil3Recruiting1
DB00291Chlorambucil3Terminated1
DB00291Chlorambucil3Unknown Status1
DB00169Cholecalciferol3Unknown Status1
DB00531Cyclophosphamide3Active Not Recruiting3
DB00531Cyclophosphamide3Completed2
DB00531Cyclophosphamide3Recruiting1
DB00531Cyclophosphamide3Terminated1
DB00091Cyclosporine3Completed1
DB12021Dinaciclib3Completed1
DB11952Duvelisib3Active Not Recruiting1
DB11952Duvelisib3Enrolling by Invitation1
DB00099Filgrastim3Terminated1
DB01073Fludarabine3Active Not Recruiting3
DB01073Fludarabine3Completed6
DB01073Fludarabine3Recruiting1
DB01073Fludarabine3Terminated1
DB09053Ibrutinib3Active Not Recruiting6
DB09053Ibrutinib3Completed1
DB09053Ibrutinib3Enrolling by Invitation1
DB09053Ibrutinib3Recruiting4
DB09054Idelalisib3Active Not Recruiting3
DB09054Idelalisib3Completed1
DB09054Idelalisib3Recruiting1
DB09054Idelalisib3Terminated2
DB09146Iron saccharate3Completed1
DB00480Lenalidomide3Active Not Recruiting1
DB00563Methotrexate3Recruiting1
DB00959Methylprednisolone3Unknown Status1
DB01204Mitoxantrone3Terminated1
DB00688Mycophenolate mofetil3Completed1
DB00688Mycophenolate mofetil3Recruiting1
DB08935Obinutuzumab3Active Not Recruiting4
DB08935Obinutuzumab3Recruiting1
DB08935Obinutuzumab3Terminated1
DB06650Ofatumumab3Active Not Recruiting2
DB06650Ofatumumab3Completed1
DB06650Ofatumumab3Enrolling by Invitation1
DB06650Ofatumumab3Recruiting1
DB00073Rituximab3Active Not Recruiting7
DB00073Rituximab3Completed3
DB00073Rituximab3Recruiting2
DB00073Rituximab3Terminated1
DB00073Rituximab3Unknown Status1
DB00877Sirolimus3Completed1
DB00864Tacrolimus3Recruiting1
DB11850Ublituximab3Active Not Recruiting2
DB11581Venetoclax3Active Not Recruiting1
DB11581Venetoclax3Recruiting3
DB06769Bendamustine4Withdrawn1
DB00531Cyclophosphamide4Unknown Status1
DB00552Pentostatin4Unknown Status1
DB00073Rituximab4Unknown Status1
DB01610Valganciclovir4Completed1
DB00087AlemtuzumabNot AvailableTerminated2
DB00074BasiliximabNot AvailableTerminated1
DB06769BendamustineNot AvailableActive Not Recruiting1
DB06769BendamustineNot AvailableRecruiting1
DB00291ChlorambucilNot AvailableRecruiting1
DB00531CyclophosphamideNot AvailableRecruiting1
DB00531CyclophosphamideNot AvailableTerminated1
DB00531CyclophosphamideNot AvailableUnknown Status1
DB00091CyclosporineNot AvailableRecruiting1
DB00091CyclosporineNot AvailableTerminated1
DB01073FludarabineNot AvailableRecruiting1
DB01073FludarabineNot AvailableTerminated1
DB01073FludarabineNot AvailableUnknown Status1
DB09053IbrutinibNot AvailableActive Not Recruiting1
DB09053IbrutinibNot AvailableRecruiting2
DB09054IdelalisibNot AvailableApproved for Marketing1
DB00480LenalidomideNot AvailableTerminated1
DB00688Mycophenolate mofetilNot AvailableRecruiting1
DB00688Mycophenolate mofetilNot AvailableTerminated1
DB08935ObinutuzumabNot AvailableNot Yet Recruiting1
DB08935ObinutuzumabNot AvailableRecruiting1
DB00073RituximabNot AvailableActive Not Recruiting1
DB00073RituximabNot AvailableApproved for Marketing1
DB00073RituximabNot AvailableRecruiting1
DB00073RituximabNot AvailableUnknown Status1
DB00313Valproic AcidNot AvailableUnknown Status1
DB11581VenetoclaxNot AvailableAvailable1